Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Metformin, a drug prescribed for patients with type 2 diabetes, has potential efficacy in enhancing antitumor immunity; however, the detailed underlying mechanisms remain to be elucidated. Therefore, we aimed to identify the inhibitory molecular mechanisms of metformin on programmed death ligand 1 (PD-L1) expression in cancer cells and programmed death 1 (PD-1) expression in immune cells. Methods: We employed a luciferase reporter assay, quantitative real-time PCR, immunoblotting analysis, immunoprecipitation and ubiquitylation assays, and a natural killer (NK) cell-mediated tumor cell cytotoxicity assay. A mouse xenograft tumor model was used to evaluate the effect of metformin on tumor growth, followed by flow-cytometric analysis using tumor-derived single-cell suspensions. Results: Metformin decreased AKT-mediated β-catenin S552 phosphorylation and subsequent β-catenin transactivation in an adenosine monophosphate-activated protein kinase (AMPK) activation-dependent manner, resulting in reduced CD274 (encoding PD-L1) transcription in cancer cells. Tumor-derived soluble factors enhanced PD-1 protein stability in NK and T cells via dissociation of PD-1 from ubiquitin E3 ligases and reducing PD-1 polyubiquitylation. Metformin inhibited the tumor-derived soluble factor-reduced binding of PD-1 to E3 ligases and PD-1 polyubiquitylation, resulting in PD-1 protein downregulation in an AMPK activation-dependent manner. These inhibitory effects of metformin on both PD-L1 and PD-1 expression ameliorated cancer-reduced cytotoxic activity of immune cells in vitro and decreased tumor immune evasion and growth in vivo. Conclusions: Metformin blocks both PD-L1 and PD-1 within the tumor microenvironment. This study provided a mechanistic insight into the efficacy of metformin in improving immunotherapy in human cancer.
Abstract
Background: Metformin, a drug prescribed for patients with type 2 diabetes, has potential efficacy in enhancing antitumor immunity; however, the detailed underlying mechanisms remain to be elucidated. Therefore, we aimed to identify the inhibitory molecular mechanisms of metformin on programmed death ligand 1 (PD-L1) expression in cancer cells and programmed death 1 (PD-1) expression in immune cells. Methods: We employed a luciferase reporter assay, quantitative real-time PCR, immunoblotting analysis, immunoprecipitation and ubiquitylation assays, and a natural killer (NK) cell-mediated tumor cell cytotoxicity assay. A mouse xenograft tumor model was used to evaluate the effect of metformin on tumor growth, followed by flow-cytometric analysis using tumor-derived single-cell suspensions. Results: Metformin decreased AKT-mediated β-catenin S552 phosphorylation and subsequent β-catenin transactivation in an adenosine monophosphate-activated protein kinase (AMPK) activation-dependent manner, resulting in reduced CD274 (encoding PD-L1) transcription in cancer cells. Tumor-derived soluble factors enhanced PD-1 protein stability in NK and T cells via dissociation of PD-1 from ubiquitin E3 ligases and reducing PD-1 polyubiquitylation. Metformin inhibited the tumor-derived soluble factor-reduced binding of PD-1 to E3 ligases and PD-1 polyubiquitylation, resulting in PD-1 protein downregulation in an AMPK activation-dependent manner. These inhibitory effects of metformin on both PD-L1 and PD-1 expression ameliorated cancer-reduced cytotoxic activity of immune cells in vitro and decreased tumor immune evasion and growth in vivo. Conclusions: Metformin blocks both PD-L1 and PD-1 within the tumor microenvironment. This study provided a mechanistic insight into the efficacy of metformin in improving immunotherapy in human cancer.
참고문헌 (37)
- Boussiotis VA, "Molecular and biochemical aspects of the PD-1 checkpoint pathway", N Engl J Med, 375, pp.1767~1778 (2016)
- Sharma P, "Primary, adaptive, and acquired resistance to cancer immunotherapy", Cell, 168, pp.707~723 (2017)
- Jiang X, "Role of the tumor microenvironment in PD-L1", PD-1-mediated tumor immune escape, 2019, pp.18, 10~
- Du L, "β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion", J Exp Med, 217, pp.e20191115~ (2020)
- Hamanishi J, "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer", Proc Natl Acad Sci U S A, 104, pp.3360~3365 (2007)
- Thompson RH, "Costimulatory B7-H1 in renal cell carcinoma patients : indicator of tumor aggressiveness and potential therapeutic target", Proc Natl Acad Sci U S A, 101, pp.17174~17179 (2004)
- Nusse R, "Wnt", β-catenin signaling, disease, and emerging therapeutic modalities, 2017, pp.169, 985~999
- Ahmadzadeh M, "Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired", Blood, 114, pp.1537~1544 (2009)
- Pesce S, "Identification of a subset of human natural killer cells expressing high levels of programmed death 1 : a phenotypic and functional characterization", J Allergy Clin Immunol, 139, pp.335~346 (2017)
- Hsu J, "Contribution of NK cells to immunotherapy mediated by PD-1", PD-L1 blockade, 2018, pp.128, 4654~4668
- Muti P, "Metformin, diet and breast cancer: an avenue for chemoprevention", Cell Cycle, 8, pp.2661~ (2009)
- Vancura A, "Metformin as an anticancer agent", Trends Pharmacol Sci, 39, pp.867~878 (2018)
- Wink KCJ, "Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer(NSCLC)using metformin during concurrent chemoradiotherapy", Radiother Oncol, 118, pp.453~459 (2016)
- Saif MW, "A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors", Cancer Chemother Pharmacol, 84, pp.1323~1331 (2019)
- Iliopoulos D, "Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types", Cancer Res, 71, pp.3196~3201 (2011)
- Zhang CS, "Metformin activates AMPK through the lysosomal pathway", Cell Metab, 24, pp.521~522 (2016)
- Dowling RJ, "Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells", Cancer Res, 67, pp.10804~10812 (2007)
- Blandino G, "Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC", Nat Commun, 3, pp.865~ (2012)
- Ben Sahra I, "Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1", Cancer Res, 71, pp.4366~4372 (2011)
- Cha JH, "Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1", Mol Cell, 71, pp.606~620 (2018)
- Lu Y, "Metformin downregulates PD-L1 expression in esophageal squamous cell carcinoma by inhibiting IL-6 signaling pathway", Front Oncol, 11, pp.762523~ (2021)
- Zhang JJ, "Metformin attenuates PD-L1expression through activating Hippo signaling pathway in colorectal cancer cells", Am J Transl Res, 11, pp.6965~6976 (2019)
- Yang W, "Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation", Nature, 480, pp.118~122 (2011)
- Rattan R, "5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase", J Biol Chem, 280, pp.39582~39593 (2005)
- Russo V, "Tumor-derived factors affecting immune cells", Cytokine Growth Factor Rev, 36, pp.79~87 (2017)
- Meng X, "FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells", Nature, 564, pp.130~135 (2018)
- Lyle C, "c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth", Sci Rep, 9, pp.20257~ (2019)
- Zhou XA, "KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression", Proc Natl Acad Sci U S A, 117, pp.28239~28250 (2020)
- Kubo T, "Study protocol : phase-Ib trial of nivolumab combined with metformin for refractory", recurrent solid tumors, 2018, pp.19, e861~e864
- Oestreich KJ, "NFATc1 regulates PD-1 expression upon T cell activation", J Immunol, 181, pp.4832~4839 (2008)
- Austin JW, "STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells", J Immunol, 192, pp.4876~4886 (2014)
- Cho HY, "Interferon-sensitive response element(ISRE)is mainly responsible for IFN-alpha-induced upregulation of programmed death-1(PD-1)in macrophages", Biochim Biophys Acta, 1779, pp.811~819 (2008)
- Terawaki S, "IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity", J Immunol, 186, pp.2772~2779 (2011)
- Tie Y, "Immunosuppressive cells in cancer : mechanisms and potential therapeutic targets", J Hematol Oncol, 15, pp.61~ (2022)
- Wang S, "Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer : results of a phase II clinical trial", Clin Cancer Res, 26, pp.4921~4932 (2020)
- Eikawa S, "Immune-mediated antitumor effect by type 2 diabetes drug, metformin", Proc Natl Acad Sci U S A, 112, pp.1809~1814 (2015)
- Crist M, "Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition", J Immunother Cancer, 10, pp.e005632~ (2022)